Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

750851

registered interest
date	11/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cerliponase Alfa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the estimated average annual cost is to the NHS of providing Brineura (Cerliponase Alfa) to someone with the CLN2 variant of Batten Disease.
tabling member constituency	Nottingham North
tabling member printed	Alex Norris
uin	4139
answer	answer is ministerial correction date of answer 18/07/2017 answer text <p>The support and care given to this group of people includes a range of treatments and supportive measures, including: anti-epileptic medication; physiotherapy; treatment for spasticity; and treatment for dystonia (including bracing and wheelchairs). Progressive feeding problems require speech and language management and gastrostomy insertion. Pain management is required for end of life care.</p><p> </p><p>Given the wide range of treatments and supportive measures, it is not possible to estimate the average annual cost of treating an individual with a Neuronal Ceroid Lipofuscinosis disease, especially since some of these costs will fall to NHS England and some to clinical commissioning groups.</p><p> </p><p>It is estimated that there are between 45 and 90 people undergoing care and treatment for all Neuronal Ceroid Lipofuscinosis diseases of whom between 19 and 38 have CLN2 and fewer than 10 have CLN5.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 4140 4141 question first answered 18/07/2017 09:59:34 answering member 4067 label Biography information for Steve Brine
tabling member	4641 label Biography information for Alex Norris

750852

registered interest
date	11/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Batten Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the average annual cost is to the NHS of care and treatment of people with (a) any Neuronal Ceroid Lipofuscinosis disease and (b) the CLN2 variant of that disease.
tabling member constituency	Nottingham North
tabling member printed	Alex Norris
uin	4140
answer	answer is ministerial correction date of answer 18/07/2017 answer text <p>The support and care given to this group of people includes a range of treatments and supportive measures, including: anti-epileptic medication; physiotherapy; treatment for spasticity; and treatment for dystonia (including bracing and wheelchairs). Progressive feeding problems require speech and language management and gastrostomy insertion. Pain management is required for end of life care.</p><p> </p><p>Given the wide range of treatments and supportive measures, it is not possible to estimate the average annual cost of treating an individual with a Neuronal Ceroid Lipofuscinosis disease, especially since some of these costs will fall to NHS England and some to clinical commissioning groups.</p><p> </p><p>It is estimated that there are between 45 and 90 people undergoing care and treatment for all Neuronal Ceroid Lipofuscinosis diseases of whom between 19 and 38 have CLN2 and fewer than 10 have CLN5.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 4139 4141 question first answered 18/07/2017 09:59:34 answering member 4067 label Biography information for Steve Brine
tabling member	4641 label Biography information for Alex Norris

750853

registered interest
date	11/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Batten Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many people in the UK are undergoing care and treatment for (a) all Neuronal Ceroid Lipofuscinosis diseases, (b) the CLN2 and (c) the CLN5 variants of that disease.
tabling member constituency	Nottingham North
tabling member printed	Alex Norris
uin	4141
answer	answer is ministerial correction date of answer 18/07/2017 answer text <p>The support and care given to this group of people includes a range of treatments and supportive measures, including: anti-epileptic medication; physiotherapy; treatment for spasticity; and treatment for dystonia (including bracing and wheelchairs). Progressive feeding problems require speech and language management and gastrostomy insertion. Pain management is required for end of life care.</p><p> </p><p>Given the wide range of treatments and supportive measures, it is not possible to estimate the average annual cost of treating an individual with a Neuronal Ceroid Lipofuscinosis disease, especially since some of these costs will fall to NHS England and some to clinical commissioning groups.</p><p> </p><p>It is estimated that there are between 45 and 90 people undergoing care and treatment for all Neuronal Ceroid Lipofuscinosis diseases of whom between 19 and 38 have CLN2 and fewer than 10 have CLN5.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 4139 4140 question first answered 18/07/2017 09:59:34 answering member 4067 label Biography information for Steve Brine
tabling member	4641 label Biography information for Alex Norris

750854

registered interest
date	11/07/2017
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Cybercrime
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, what targets she has set for local police forces to tackle cybercrime; and how work to meet those targets will be funded.
tabling member constituency	Nottingham North
tabling member printed	Alex Norris
uin	4153
answer	answer is ministerial correction date of answer 19/07/2017 answer text <p>The Home Office is committed to not placing unnecessary bureaucratic burdens on the police and has scrapped all central targets. However, Chief Constables are under a duty to comply with the Strategic Policing Requirement (SPR). The SPR provides a framework for consistent, collective decision making by forces, but leaves the specifics of how this should be achieved to Chief Constables.</p><p>The Strategic Policing Requirements describes organised crime, including large scale cyber crime, as a national threat that Chief Constables and Police and Crime Commissioners are expected to plan and prepare, together or in support of national arrangements, to address these threats.</p><p>The National Police Chiefs’ Council has oversight of force contributions to the SPR. Police and Crime Commissioners are required to hold Chief Constables to account for the delivery of the SPR and to have regard to the SPR when producing their police and crime plans. The Home Office also continue to support forces in building professional responsibility through the College of Policing; and returning accountability to the public through Police and Crime Commissioners.</p><p>The 2015 National Security Strategy confirmed that cyber remains a top threat to the UK’s economic and national security. The UK’s future security and prosperity depends on our ability to safeguard digital information, data and networks at home and abroad. The cyber threats we face continue to grow in scale and sophistication. This is why the National Cyber Security Strategy 2016-2021 is supported by £1.9billion of transformational investment.</p><p>Through the National Cyber Security Programme, we invested over £90 million under the 2010-15 Parliament to bolster the law enforcement response. The Government will continue to invest in law enforcement capabilities at the national, regional and local levels to ensure delivery agencies have the capacity to deal with the increasing volume and sophistication of cyber crime. We are increasing the capabilities of the National Crime Agency’s National Cyber Crime Unit by increasing their ability to investigate the most serious cyber crime.</p> answering member constituency Wyre and Preston North answering member printed Mr Ben Wallace question first answered 19/07/2017 16:51:51 answering member 1539 label Biography information for Mr Ben Wallace
tabling member	4641 label Biography information for Alex Norris

751586

registered interest
date	10/07/2017
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Railways: Franchises
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Transport, what assessment he has made of the costs and benefits of rail franchising.
tabling member constituency	Nottingham North
tabling member printed	Alex Norris
uin	900473
answer	answer is ministerial correction date of answer 13/07/2017 answer text <p>The benefits of franchising to passengers and taxpayers are clear. The private sector have invested billions in new trains. Government subsidy to the industry has reduced by £2.5bn over ten years. Whilst passenger numbers have doubled since privatisation.</p><p> </p><p>All this is on top of our ongoing £38bn investment in infrastructure. We always assess franchising decisions against the best interests of passengers and taxpayers.</p><p> </p> answering member constituency Blackpool North and Cleveleys answering member printed Paul Maynard question first answered 13/07/2017 15:33:46 answering member 3926 label Biography information for Paul Maynard
tabling member	4641 label Biography information for Alex Norris